Cyclical Breast Pain Research Articles

The breast pain clinic: a rational approach to classification and treatment of breast pain.

Three hundred and fifty women complaining of breast pain symptoms of sufficient severity to interfere with their normal lifestyle were reviewed in a special breast pain clinic over a 5 year period. Seventy-two patients (21%) had spontaneous resolution of breast pain and they required reassurance only before discharge. Of the remaining 278 patients, accurate classification of breast pain syndromes was achieved in 89%, the commonest syndrome being cyclical breast pain which accounted for 54% of the women followed up. The remaining womens' breast pain was classified as trigger zone (14%), continuous (8%), Tietze's disease (5%), spinal root (4%), duct ectasia (4%) and psychological depression (2%). In the remaining 25 patients (9%) the breast pain could not be classified. The experience from this clinic is that a majority of women complaining of severe breast pain symptoms can be accurately classified and appropriate therapy instituted.

A double‐blind controlled trial of danazol and bromocriptine in the management of severe cyclical breast pain

International Journal of Clinical PracticeVolume 40, Issue 8 p. 326-330 Clinical Study A double-blind controlled trial of danazol and bromocriptine in the management of severe cyclical breast pain C P Hinton FRCS, Corresponding Author C P Hinton FRCS n/[email protected] City Hospital, NottinghamCorrespondence to: Mr C P Hinton, University Hospital, Queen's Medical Centre, Nottingham, NG7 2UH.Search for more papers by this authorH M Bishop FRCS, H M Bishop FRCS City Hospital, NottinghamSearch for more papers by this authorH W Holliday FRCS, H W Holliday FRCS City Hospital, NottinghamSearch for more papers by this authorP J Doyle FRCS, P J Doyle FRCS City Hospital, NottinghamSearch for more papers by this authorR W Blamey MD, FRCS, R W Blamey MD, FRCS City Hospital, NottinghamSearch for more papers by this author C P Hinton FRCS, Corresponding Author C P Hinton FRCS n/[email protected] City Hospital, NottinghamCorrespondence to: Mr C P Hinton, University Hospital, Queen's Medical Centre, Nottingham, NG7 2UH.Search for more papers by this authorH M Bishop FRCS, H M Bishop FRCS City Hospital, NottinghamSearch for more papers by this authorH W Holliday FRCS, H W Holliday FRCS City Hospital, NottinghamSearch for more papers by this authorP J Doyle FRCS, P J Doyle FRCS City Hospital, NottinghamSearch for more papers by this authorR W Blamey MD, FRCS, R W Blamey MD, FRCS City Hospital, NottinghamSearch for more papers by this author First published: 01 August 1986 https://doi.org/10.1111/j.1742-1241.1986.tb07992.xRead the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Volume40, Issue8August 1986Pages 326-330 RelatedInformation

Serum oestradiol-17β and prolactin concentrations during the luteal phase in women with benign breast disease

Serum profiles of both oestradiol and prolactin were measured during the luteal phase in normal women, in women with cyclical breast pain and in women with recently biopsied benign breast disease. The results suggest that, in women with benign breast disease, the concentration of both hormones may be increased, when compared to the normal controls, during the evening in the latter part of the luteal phase.

Serum progesterone concentration during the luteal phase in women with benign breast disease

Earlier studies of the serum concentration of progesterone during the luteal phase in women with benign breast disease have produced conflicting results. Serum progesterone profiles were therefore measured in relation to cyclical breast pain and in biopsied benign disease. No evidence of progesterone deficiency was found.

Treatment of Cyclical Breast Pain with Bromocriptine

Bromocriptine 2.5 mg. twice daily was given to 38 patients with cyclical breast pain and 15 with a non-cyclical pattern in a double blind trial lasting 6 cycles. Response to treatment was assessed by both clinician and patients independently and serum prolactin levels were monitored. Cyclical breast pain was significantly improved by bromocriptine but non-cyclical pain failed to respond. Although most patients were normoprolactinaemic before the trial, bromocriptine therapy produced a significant depression of the mean serum prolactin level.